Biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) announced on Tuesday that it has completed patient enrollment in the ELEVATE IPF Phase 2b trial for LYT-100, a deuterated form of pirfenidone, targeting idiopathic pulmonary fibrosis (IPF).

The trial compares LYT-100's efficacy and tolerability against placebo and pirfenidone, with topline results anticipated in Q4 2024.

LYT-100 aims to address tolerability issues associated with current IPF treatments while maintaining efficacy. The trial, designed to evaluate multiple doses of LYT-100, employs validated endpoints and Bayesian analysis for primary efficacy assessment.

PureTech plans to leverage trial results for potential registration in the US and other regions, aiming to provide enhanced therapy options for IPF patients. The company expresses appreciation for trial participants and stakeholders involved in advancing LYT-100's development.

IPF is a rare, progressive lung disease with limited treatment options. LYT-100, a deuterated form of pirfenidone, seeks to improve tolerability while maintaining therapeutic efficacy.

PureTech Health is dedicated to developing innovative therapies to address unmet medical needs.